ID   MCF-12A
AC   CVCL_3744
SY   MCF12A; Michigan Cancer Foundation-12A
DR   BTO; BTO:0002544
DR   CLO; CLO_0007603
DR   CLO; CLO_0037180
DR   EFO; EFO_0001202
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; CRL-3598
DR   ATCC; CRL-10782
DR   BioSample; SAMN03472816
DR   ChEMBL-Cells; CHEMBL3307365
DR   ChEMBL-Targets; CHEMBL614322
DR   Cosmic; 1017163
DR   Cosmic; 1136378
DR   Cosmic; 1176637
DR   Cosmic; 2560249
DR   DepMap; ACH-002327
DR   GEO; GSM756372
DR   GEO; GSM845396
DR   GEO; GSM844585
DR   GEO; GSM1053717
DR   GEO; GSM1172975
DR   GEO; GSM1172884
DR   GEO; GSM1238117
DR   LINCS_HMS; 51089
DR   PharmacoDB; MCF12A_894_2019
DR   PRIDE; PXD005339
DR   PubChem_Cell_line; CVCL_3744
DR   TOKU-E; 2381
DR   Wikidata; Q54904301
RX   Patent=US5206165;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25960936;
RX   PubMed=28287265;
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10782.
CC   Population: Caucasian.
CC   Doubling time: ~19 hours (ATCC=CRL-3598); 35.42 hours (JWGray panel).
CC   HLA typing: A*66:01,02:01; B*41:02,18:01/35:08; C*07:01,17:01; DRB1*11:67,11:67 (PubMed=25960936).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: ATCC; CRL-10782; true.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
ST   Source(s): ATCC=CRL-3598
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9,11
ST   D16S539: 9,12
ST   D18S51: 18
ST   D19S433: 13,15
ST   D21S11: 28,30
ST   D2S1338: 19
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 10,13
ST   FGA: 23,26
ST   Penta D: 9,12
ST   Penta E: 7,10
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_3745 ! MCF-12F
SX   Female
AG   63Y
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
RX   Patent=US5206165;
RA   Pauley R.J., Paine T.J., Soule H.D.;
RT   "Immortal human mammary epithelial cell sublines.";
RL   Patent number US5206165, 27-Apr-1993.
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).